, Volume 5, Issue 1, pp 20–21 | Cite as

Therapie immunkompetenter Patienten

Addition von Cetuximab zur Radiochemotherapie von Analkarzinomen

journal club


  1. 1.
    James RD et al. Lancet Oncol 2013;14(6):516–24CrossRefPubMedGoogle Scholar
  2. 2.
    Garg MK et al. J Clin Oncol 2017;35(7):718–26CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gunderson LL et al. J Clin Oncol 2012;30(35):4344–51CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Glynne-Jones R et al. Lancet Oncol 2017;18(3):347–56CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Doll CM et al. Int J Radiat Oncol Biol Phys 2017;97(3):554–62CrossRefPubMedGoogle Scholar
  6. 6.
    Yates A et al. Clin Oncol (R Coll Radiol) 2015;27(12):700–7CrossRefGoogle Scholar
  7. 7.
    Erstpubliziert in Strahlenther Onkol 2017;193(6):508-9Google Scholar


  1. Garg MK. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 2017;35(7):718–26CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Dept. of Oncology and Palliative MedicineNordland Hospital TrustBodøNorwegen

Personalised recommendations